Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Based on IIEF-5, 68.1% of patients had ED and according to AMSS 36.8%, 27.2% and 5.3% of men had symptoms compatible with mild, moderate and severe androgen deficiency, respectively.Clinical and biochemical data of patients and comparison between men with frankly low vs low vs normal TT (nmol/l)OverallTT < 8 (n = 25)8 ≤ TT < 12 (n = 52)TT ≥ 12 (n = 113)pAge (year)58.0 (51.0 to 64.0)59.0 (54.0 to 65.0)57.5 (48.7 to 62.7)58.0 (51.0 to 65.0)0.583BMI (kg/m2)28.4 (25.8 to 31.1)31.4 (29.6 to 34.9)28.8 (26.8 to 32.1)27.9 (25.0 to 30.7)0.008Waist circumference (cm)101.0 (94.0 to 109.2)115.0 (105.5 to 118.5)102.5 (96.2 to 111.0)99.0 (92.7 to 107.2)< 0.001Glycemia (mg/dl)142.0 (122.0 to 175.0)159.0 (137.0 to 184.0)154.0 (126.7 to 183.2)137.0 (120 to 0-164.0)0.024HbA1c (%)7.2 (6.6 to 8.1)7.4 (6.9 to 8.5)7.3 (6.6 to 8.6)6.9 (6.5 to 7.8)0.0028Total cholesterol (mg/dl)174.0 (154.0 to 197.0)189.0 (163.0 to 2225.0)175.0 (156.2 to 200.2)173.0 (157.0 to 192.0)0.189HDL cholesterol (mg/dl)44.0 (38.0 to 54.0)41.0 (33.0 to 50.0)40.5 (35.0 to 44.2)46.0 (40.0 to 56.0)0.021Non-HDL cholesterol (mg/dl)113.0 (87.8 to 131.0)121.0 (96.4 to 138.0)122.0 (97.2 to 153.0)112.0 (89.8 to 129.0)0.067Triglycerides (mg/dl)121.0 (87.0 to 187.0)177.0 (143.0 to 245.0)164.5 (114.7 to 216.2)101.0 (82.0 to 132.0)< 0.001Creatinine (mg/dl)0.8 (0.7 to 0.9)0.9 (0.7 to 1.0)0.9 (0.8 to 1.0)0.8 (0.7 to 0.9)0.380LH (IU/l)5.0 (3.8 to 6.9)5.7 (4.2 to 9.1)5.4 (4.0 to 8.0)5.0 (3.8 to 6.2)0.324TT (nmol/l)12.9 (10.2 to 16.6)6.8 (5.6 to 7.8.0)9.2 (8.7 to 11.4)15.3 (13.1 to 18.7)< 0.001E2 (pmol/l)82.0 (55.2 to 105.0)54.0 (39.0 to 87.2)84.0 (59.5 to 101.5)86.5 (59.2 to 109.0)0.132PSA (ng/ml)0.9 (0.5 to 1.6)0.7 (0.3 to 1.0)0.8 (0.5 to 1.6)1.0 (0.6 to 1.9)0.16125 OH-Vitamin D (nmol/l)33.5 (20.0 to 49.0)21.5 (15.7 to 31.5)33.0 (17.5 to 45.0)38.0 (23.5 to 49.5)0.016Right testicular volume (ml)14.0 (12.0 to 16.7)14.0 (11.0 to 16.0)16.0 (13.6 to 18.0)14.0 (12.0 to 18.0)0.682Left testicular volume (ml)14.0 (12.0 to 16.0)13.5 (11.0 to 16.2)14.0 (12.0 to 16.0)14.0 (12.0 to 17.0)0.709Erectile dysfunction (%)68.1%77.3%79.274.1%0.694IIEF-517.0 (8.0 to 22.0)11.5 (7.0 to 20.0)11.0 (6.7 to 20.0)17.0 (9.0 to 22.0)0.095IPSS6.0 (2.0 to 11.0)6.5 (4.0 to 12.5)7.0 (3.0 to 12.5)5.0 (2.0 to 10.0)0.325AMSS31.0 (24.0 to 40.0)32.0 (29.0 to 45.0)34.5 (29.0 to 40.7)29.0 (22.0 to 38.0)0.018VAI3.7 (2.4 to 6.4)6.5 (3.9 to 10.8)6.0 (3.8 to 8.9)3.0 (2.2 to 4.3)< 0.001TyG4.9 (4.7 to 5.1)5.1 (5.0 to 5.3)5.0 (4.8 to 5.3)4.8 (4.6 to 4.9)< 0.001LAP50.3 (33.5 to 83.0)90.6 (69.9 to 151.2)67.2 (49.4 to 109.6)39.5 (26.5 to 54.3)< 0.001Anti-hypercholesterolemic therapy (%)59.9%61.3%60.2%54.9%0.459Anti-hypertensive therapy (%)65.8%64.6%65.9%65.5%0.838Anti-hyperglycemic drugs (%)88.9%87.3%88.1%89.6%0.733Significant p values are in boldData are expressed as median (IQR) for continuous variables and as absolute number (%) for categorical variables.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

265 consecutive men aged 40 to 70 years with type 2 diabetes performed an andrological evaluation; metabolic parameters and TT were determined.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes

Study design awaiting verification · Journal of Endocrinological Investigation · 2022

Original publication title

Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes

N. Caretta; P. Facondo; S. Mereu; A. Delbarba; M. C. Crepaldi; M. Vedovato; A. Avogaro; A. Ferlin

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This is the first study evaluating the association of VAI, TyG, and LAP with hypogonadism in men with type 2 diabetes. Alterations in these indices should direct the patients to andrological evaluation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To evaluate in men with type 2 diabetes the association of cardiometabolic indices [Visceral Adiposity Index (VAI), Triglyceride Glucose Index (TyG), and lipid accumulation product (LAP)] with total testosterone (TT) levels, and their predictive cut-off values in identifying hypogonadism.

Source: Purpose

Abstract: What methods does the paper describe?

265 consecutive men aged 40 to 70 years with type 2 diabetes performed an andrological evaluation; metabolic parameters and TT were determined. Receiver operating characteristic (ROC) curves were used to identify cut-off values of cardiometabolic indices in predicting low testosterone (TT < 12 nmol/l).

Source: Methods

Abstract: Results

VAI, TyG, and LAP were negatively associated with TT levels. The prevalence of hypogonadism in men in the fourth quartiles of VAI, TyG, and LAP was ~ 70.0 to 75.0% compared to ~ 10.0 to 17.0% in men in the first quartiles (p < 0.001). The sensitivity and specificity of the three cardiometabolic indices in predicting TT < 12 nmol/l were significantly higher concerning BMI, waist circumference, lipid profile and HbA1c. Cut off values of VAI ≥ 3.985, TyG ≥ 4.925, and LAP ≥ 51.645 predict hypogonadism with good sensitivity and specificity.

Source: Results

Abstract: Conclusion

This is the first study evaluating the association of VAI, TyG, and LAP with hypogonadism in men with type 2 diabetes. Alterations in these indices should direct the patients to andrological evaluation.

Source: Conclusion
Authors’ abstract

Purpose

To evaluate in men with type 2 diabetes the association of cardiometabolic indices [Visceral Adiposity Index (VAI), Triglyceride Glucose Index (TyG), and lipid accumulation product (LAP)] with total testosterone (TT) levels, and their predictive cut-off values in identifying hypogonadism.

Methods

265 consecutive men aged 40 to 70 years with type 2 diabetes performed an andrological evaluation; metabolic parameters and TT were determined. Receiver operating characteristic (ROC) curves were used to identify cut-off values of cardiometabolic indices in predicting low testosterone (TT < 12 nmol/l).

Results

VAI, TyG, and LAP were negatively associated with TT levels. The prevalence of hypogonadism in men in the fourth quartiles of VAI, TyG, and LAP was ~ 70.0 to 75.0% compared to ~ 10.0 to 17.0% in men in the first quartiles (p < 0.001). The sensitivity and specificity of the three cardiometabolic indices in predicting TT < 12 nmol/l were significantly higher concerning BMI, waist circumference, lipid profile and HbA1c. Cut off values of VAI ≥ 3.985, TyG ≥ 4.925, and LAP ≥ 51.645 predict hypogonadism with good sensitivity and specificity.

Conclusion

This is the first study evaluating the association of VAI, TyG, and LAP with hypogonadism in men with type 2 diabetes. Alterations in these indices should direct the patients to andrological evaluation.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40618-022-01941-0.

Publication and source details

Original title: Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes

N. Caretta; P. Facondo; S. Mereu; A. Delbarba; M. C. Crepaldi; M. Vedovato; A. Avogaro; A. Ferlin

Journal of Endocrinological Investigation · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Padova

Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T22:02:45.490211+00:00

DOI: 10.1007/s40618-022-01941-0 · PMC9938038